157 related articles for article (PubMed ID: 7214106)
1. Clinical state, plasma levels of haloperidol and prolactin: a correlation study in chronic schizophrenia.
Rao VA; Bishop M; Coppen A
Br J Psychiatry; 1980 Dec; 137():518-21. PubMed ID: 7214106
[TBL] [Abstract][Full Text] [Related]
2. [A double-blind study of metoclopramide in the treatment of schizophrenia and determination of prolactin].
Gu SF
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1992 Dec; 25(6):328-30, 382. PubMed ID: 1304992
[TBL] [Abstract][Full Text] [Related]
3. [Standard and high doses of haloperidol. Clinical, pharmacokinetic and pharmacodynamic aspects].
Schilkrut R; Haverbeck C; Duran E; Delgado S; Kohen P; Birkner R; Katz I
Acta Psiquiatr Psicol Am Lat; 1981; 27(4-5):315-24. PubMed ID: 7348089
[TBL] [Abstract][Full Text] [Related]
4. Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients.
Yasui-Furukori N; Kondo T; Suzuki A; Mihara K; Kaneko S; Otani K
Prog Neuropsychopharmacol Biol Psychiatry; 2002 Apr; 26(3):575-8. PubMed ID: 11999910
[TBL] [Abstract][Full Text] [Related]
5. Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays.
Smith RC; Baumgartner R; Misra CH; Mauldin M; Shvartsburd A; Ho BT; DeJohn C
Arch Gen Psychiatry; 1984 Nov; 41(11):1044-9. PubMed ID: 6497566
[TBL] [Abstract][Full Text] [Related]
6. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine.
Kapur S; Roy P; Daskalakis J; Remington G; Zipursky R
Am J Psychiatry; 2001 Feb; 158(2):311-4. PubMed ID: 11156818
[TBL] [Abstract][Full Text] [Related]
7. Biperiden and haloperidol plasma levels and extrapyramidal side effects in schizophrenic patients.
Meszaros K; Lenzinger E; Hornik K; Schönbeck G; Hatzinger R; Langer G; Sieghart W; Aschauer HN
Neuropsychobiology; 1997; 36(2):69-72. PubMed ID: 9267855
[TBL] [Abstract][Full Text] [Related]
8. Plasma concentrations of remoxipride and haloperidol in relation to prolactin and short-term therapeutic outcome in schizophrenic patients.
Lahdelma RL; Appelberg B; Kuoppasalmi K; Katila H; Rimón R
Eur Neuropsychopharmacol; 1991 Dec; 1(4):535-40. PubMed ID: 1688013
[TBL] [Abstract][Full Text] [Related]
9. A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients.
Lin KM; Poland RE; Nuccio I; Matsuda K; Hathuc N; Su TP; Fu P
Am J Psychiatry; 1989 Oct; 146(10):1307-11. PubMed ID: 2782476
[TBL] [Abstract][Full Text] [Related]
10. Determination of plasma haloperidol concentrations by radioreceptor assay in schizophrenia: clinical utility.
Santos JL; Ramos JA; Prieto P; Almoguera I; Vazquez C; Rubio ME; Cabranes JA
Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(6):917-25. PubMed ID: 2813809
[TBL] [Abstract][Full Text] [Related]
11. A clinical and pharmacodynamic evaluation of sulpiride.
Rao VA; Bailey J; Bishop M; Coppen A
Psychopharmacology (Berl); 1981; 73(1):77-80. PubMed ID: 6785794
[TBL] [Abstract][Full Text] [Related]
12. Effect of the CYP2D6 genotype on prolactin concentration in schizophrenic patients treated with haloperidol.
Yasui-Furukori N; Kondo T; Suzuki A; Mihara K; Tokinaga N; Inoue Y; Otani K; Kaneko S
Schizophr Res; 2001 Oct; 52(1-2):139-42. PubMed ID: 11595402
[No Abstract] [Full Text] [Related]
13. Neuroendocrine tests during treatment with neuroleptic drugs I. Plasma prolactin response to haloperidol challenge.
Kolakowska T; Braddock L; Wiles D; Franklin M; Gelder M
Br J Psychiatry; 1981 Nov; 139():400-4. PubMed ID: 6120731
[TBL] [Abstract][Full Text] [Related]
14. Serum haloperidol determinations in psychiatric patients. Comparison of methods and correlation with serum prolactin level.
Rubin RT; Forsman A; Heykants J; Ohman R; Tower B; Michiels M
Arch Gen Psychiatry; 1980 Sep; 37(9):1069-74. PubMed ID: 7416906
[TBL] [Abstract][Full Text] [Related]
15. Prolactin monitoring of haloperidol and pimozide treatment in children with Tourette's syndrome.
Sallee FR; Dougherty D; Sethuraman G; Vrindavanam N
Biol Psychiatry; 1996 Nov; 40(10):1044-50. PubMed ID: 8915564
[TBL] [Abstract][Full Text] [Related]
16. High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin.
Bjørndal N; Bjerre M; Gerlach J; Kristjansen P; Magelund G; Oestrich IH; Waehrens J
Psychopharmacology (Berl); 1980 Jan; 67(1):17-23. PubMed ID: 6768075
[No Abstract] [Full Text] [Related]
17. Comparison of prolactin concentrations between haloperidol and risperidone treatments in the same female patients with schizophrenia.
Yasui-Furukori N; Kondo T; Suzuki A; Mihara K; Kaneko S
Psychopharmacology (Berl); 2002 Jun; 162(1):63-6. PubMed ID: 12107619
[TBL] [Abstract][Full Text] [Related]
18. Elevation of plasma concentrations of haloperidol after the addition of fluoxetine.
Goff DC; Midha KK; Brotman AW; Waites M; Baldessarini RJ
Am J Psychiatry; 1991 Jun; 148(6):790-2. PubMed ID: 2035723
[TBL] [Abstract][Full Text] [Related]
19. Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo.
Eklund K; Forsman A
Clin Neuropharmacol; 1991; 14 Suppl 2():S7-12; discussion S12-5. PubMed ID: 1684310
[TBL] [Abstract][Full Text] [Related]
20. Prolactin response and extrapyramidal side effects during propranolol and neuroleptic drugs treatment in chronic schizophrenic patients.
Elizur A; Segal S; Yeret A; Ben-David M
Isr Ann Psychiatr Relat Discip; 1979 Dec; 17(4):318-27. PubMed ID: 44877
[No Abstract] [Full Text] [Related]
[Next] [New Search]
